StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) bonds

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.04+0.06 (+0.55%)

Close on Nov 17, 2026Market cap $5.40BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Gossamer Bio reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2019

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Gossamer Bio's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
2030 Notes
Convertible
–2030–$65.20M
2030 Notes
Convertible
7.50%2030––
2027 Notes
Convertible
5.00%–$181.05M$18.90M
2027 and 2030 Notes–––$84.12M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailable
Credit Facility$150.00M$120.00M

See a number that looks wrong?